ARICEUM
LIVE

Serial Number

79350973

Owner

Ariceum Therapeutics GmbH

Attorney

Molly Buck Richard

Filing Date

Aug 22, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ARICEUM Trademark

Serial Number: 79350973 • Registration: 7318209

ARICEUM is a trademark filed by Ariceum Therapeutics GmbH on August 22, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Ariceum Therapeutics GmbH (2 trademarks)

Robert-Rössle-Straße 10, Haus 79

Entity Type: 27

Trademark Details

Filing Date

August 22, 2022

Registration Date

March 5, 2024

Published for Opposition

December 19, 2023

Goods & Services

Pharmaceuticals for use in the treatment of cancer; pharmaceutical drugs for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of cancer; injectable pharmaceuticals for use in the treatment of cancer; chemico-pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations and substances for use in the treatment of cancer; pharmaceutical preparations for human use for use in the treatment of cancer; synthetic peptides for pharmaceutical purposes for use in the diagnosis and treatment of cancer; pharmaceutical preparations for medical purposes for use in the treatment of cancer; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; radioactive substances for medical purposes; radioactive materials for medical purposes; radioactive elements for medical use

Pharmaceutical products development; pharmaceutical product evaluation; testing of pharmaceuticals; research of pharmaceuticals; pharmaceutical research and development; research relating to pharmaceuticals; conducting clinical trials for pharmaceutical products of others; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; research and development for the pharmaceutical industry; research and development in the pharmaceutical and biotechnology fields; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations for treating malignant tumours

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 12, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 12, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 12, 2025 REAP
NEW REPRESENTATIVE AT IB RECEIVED
Aug 16, 2024 NREP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 6, 2024 FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 6, 2024 FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 6, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 5, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 5, 2024 R.PR
NOTIFICATION PROCESSED BY IB
Dec 19, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 19, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 29, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 29, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 13, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 10, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 9, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 9, 2023 TROA
REFUSAL PROCESSED BY IB
Aug 7, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 20, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jul 20, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 15, 2023 RFCR
NON-FINAL ACTION WRITTEN
Jun 14, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 8, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 4, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 30, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 29, 2022 REPR